Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucosidase, beta, acid | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.0312 | 0.325 | 0.325 |
Brugia malayi | O-Glycosyl hydrolase family 30 protein | 0.0312 | 0.325 | 0.325 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0231 | 0.1586 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Loa Loa (eye worm) | angiotensin-converting enzyme family protein | 0.0641 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.0205 | 0.105 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0231 | 0.1586 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.1276 | 0.1027 |
Wolbachia endosymbiont of Brugia malayi | extracellular metallopeptidase | 0.0313 | 0.3265 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 0.325 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.1276 | 0.1027 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 127 nM | BindingDB_Patents: Enzyme Inhibition Assay. The enzyme inhibition assays used monitored the ability of a test compound to bind and prevent the hydrolysis of a fluorogenic substrate in a concentration-dependent mariner. Specifically, the enzyme activity of recombinant human GCase (rhGCase; Cerezyme, Genzyme Corp.) was measured using the 4-methylumbelliferyl-ß-D-glucopyranoside (4-MU-ß-D-Glc) fluorogenic substrate in the absence or in the presence of varying amounts of each test compound. | ChEMBL. | No reference |
IC50 (binding) | = 659 nM | BindingDB_Patents: Enzyme Inhibition Assay. The enzyme inhibition assays used monitored the ability of a test compound to bind and prevent the hydrolysis of a fluorogenic substrate in a concentration-dependent mariner. Specifically, the enzyme activity of recombinant human GCase (rhGCase; Cerezyme, Genzyme Corp.) was measured using the 4-methylumbelliferyl-ß-D-glucopyranoside (4-MU-ß-D-Glc) fluorogenic substrate in the absence or in the presence of varying amounts of each test compound. | ChEMBL. | No reference |
Ki (binding) | = 67 nM | BindingDB_Patents: Enzyme Inhibition Assay. The enzyme inhibition assays used monitored the ability of a test compound to bind and prevent the hydrolysis of a fluorogenic substrate in a concentration-dependent mariner. Specifically, the enzyme activity of recombinant human GCase (rhGCase; Cerezyme, Genzyme Corp.) was measured using the 4-methylumbelliferyl-ß-D-glucopyranoside (4-MU-ß-D-Glc) fluorogenic substrate in the absence or in the presence of varying amounts of each test compound. | ChEMBL. | No reference |
Ki (binding) | = 273 nM | BindingDB_Patents: Enzyme Inhibition Assay. The enzyme inhibition assays used monitored the ability of a test compound to bind and prevent the hydrolysis of a fluorogenic substrate in a concentration-dependent mariner. Specifically, the enzyme activity of recombinant human GCase (rhGCase; Cerezyme, Genzyme Corp.) was measured using the 4-methylumbelliferyl-ß-D-glucopyranoside (4-MU-ß-D-Glc) fluorogenic substrate in the absence or in the presence of varying amounts of each test compound. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.